



HAL
open science

Multidrug resistance-associated protein 4 in pharmacology: Overview of its contribution to pharmacokinetics, pharmacodynamics and pharmacogenetics

Joseph Berthier, Hélène Arnion, Franck Saint-Marcoux, Nicolas Picard

► To cite this version:

Joseph Berthier, Hélène Arnion, Franck Saint-Marcoux, Nicolas Picard. Multidrug resistance-associated protein 4 in pharmacology: Overview of its contribution to pharmacokinetics, pharmacodynamics and pharmacogenetics. *Life Sciences*, 2019, 231, pp.116540 -. <10.1016/j.lfs.2019.06.015>. <hal-03484644>

HAL Id: hal-03484644

<https://hal.science/hal-03484644v1>

Submitted on 20 Dec 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons CC BY-NC 4.0 - Attribution - Non-commercial use - International License

Multidrug Resistance-Associated Protein 4 in pharmacology: overview of its contribution to pharmacokinetics, pharmacodynamics and pharmacogenetics

BERTHIER Joseph^{a,b}, ARNION H el ene^a, SAINT-MARCOUX Franck^{a,b}, PICARD Nicolas^{a,b}

^a INSERM, UMR 1248, F-87000 Limoges, France;

^b CHU Limoges, Service de pharmacologie, toxicologie et pharmacovigilance, F-87000 Limoges, France.

Correspondence: CHU Limoges, B atiment CBRS, Service de Pharmacologie, Toxicologie et Pharmacovigilance, 2 avenue Martin-Luther King F-87042 Limoges, France. Tel: +33 555056140, Fax: +33 555056162, E-mail address: nicolas.picard@unilim.fr (Nicolas Picard)

Abstract

MRP4 is an ABC membrane transporter involved in clinical outcomes as it is located in many tissues that manages the transport and the elimination of many drugs. This review explores the implication of MRP4 in clinical pharmacology and the importance of its genetic variability. Although there is no specific recommendation regarding the study of MRP4 in drug development, it should be considered when drugs are eliminated by the kidney or liver or when drug-drug interactions are expected.

Keywords: pharmacogenetics, drug-drug interactions, Multidrug Resistance-Associated Protein 4, anti-infectious and anti-cancer drugs.

1. INTRODUCTION

The transport of xenobiotics across organ membranes is mediated by transporters related to the ATP-binding cassette (ABC) transporter or the Solute Carrier (SLC) superfamilies. The present review focuses on MRP4 (Multidrug resistance-associated protein 4), the fourth member of the ABCC family (*ABCC4* gene). MRP4 acts as an unidirectional export pump for conjugates which contributes to cellular detoxification. This transporter has been much less considered than other important members of the ABC superfamily such as the P-glycoprotein (P-gp, ABCB1). However, MRP4 obviously has an important role in clinical pharmacology since it contributes to the export of xenobiotics and it is known to be associated with situations of multi-drug resistance.

MRP4 is encoded by the *ABCC4* gene (MRP4 refers to the protein). Its substrates are mainly organic anions and glucuronide conjugates. [1,2] According to Genecards (<https://www.genecards.org/cgi-bin/carddisp.pl?gene=ABCC4&keywords=ABCC4>) this gene is located on the minus strand of chromosome 13 (GRCh38/hg38: 95,019,829-95,301,475). The related protein is composed of 1325 amino acids and has a molecular mass of 149.5 KDa. Alternative splicing leads to 4 isoforms of MRP4.

So far, only isoform #1 has been studied. It is expressed in different organs such as the brain, liver, kidneys and blood cells [3] (Figure 1). MRP4 contains two transmembrane domains (TMDs) and two nucleotide binding domains (NBDs) where the catalytic sites are found [4] (Figure 2)

2. The roles of MRP4 in pharmacology

2.1 Substrates, inhibitors and related clinical application fields

Table 1 shows the main substrates and inhibitors of MRP4 as reported by Ivanyuk *et al.* and Russel *et al.* [5,6]. The drugs are related to 9 different clinical domains. Several substrates belong to cardiovascular, anti-infectious and anti-cancer drugs. In most cases these substrates are also inhibitors.

2.2 The role of MRP4 in drug pharmacokinetics

MRP4 is present in multiple organs and can modify cellular exposure to drugs or metabolites with different consequences. Here, we address the expected role of MRP4 in major organs involved in pharmacokinetics. Most of the studies listed below were performed in animals or derived from *in vitro* data. Extrapolation from these studies to clinical pharmacokinetics in humans requires careful interpretation.

Kidney

MRP4 is localized at the apical membrane of kidney proximal tubules (figure 1B) where it participates in the elimination of many drugs [2]. Various studies have shown that the absence of MRP4 can lead to an accumulation of the drugs in kidney cells and significantly modify their tubular excretion.

This phenomenon has been demonstrated for cephalosporins when administered to mice [7]. Ci *et al.* reported that intra-kidney concentrations of ceftizoxime and cefazolin was 2 to 3-fold higher in *Mrp4*^{-/-} mice compared to wild-type mice. The accumulation of the two drugs in the kidney was found to decrease the renal clearances (about 10-fold and 3-fold, respectively) of both drugs, but was not associated with a significant modification in their steady-state plasma concentrations [7].

In a very similar study, Hasegawa *et al.* observed that the clearance of two different diuretics

(hydrochlorothiazide and furosemide) was reduced of about 35 to 40% in *Mrp4*^{-/-} mice [8]. In deficient mice, the intra-kidney concentration of hydrochlorothiazide was almost doubled as compared to wild-type mice. Here again, the accumulation in the kidney and decrease in the renal excretion of the diuretics was not associated with a modification in drug plasma concentrations (similar area under the time-concentration (AUC) values of furosemide in deficient and control mice).

The same research team also demonstrated that the absence of MRP4 could double the intra-kidney concentrations of tenofovir and adefovir, two antiviral agents with strong and selective activity against retroviruses [9]. For both drugs, the renal luminal efflux clearance was estimated to be 37% in *Mrp4*^{-/-} mice and 46% in wild-type mice [9].

Brain

MRP4 is localized in the basolateral membrane of the choroid plexus epithelium and also at the luminal side of brain capillaries (figure 1A) [10]. It reduces the transfer of many xenobiotics into the brain by extruding them from blood capillaries to the plasma. The impact of this phenomenon has been explored for different classes of drugs.

Some authors have focused on anticancer drugs because accumulation into the brain can promote neurotoxicity. Leggas *et al.* reported that 6 hours after an intravenous injection of 2 mg/kg of topotecan, whole-brain concentration of the drug was approximately six times higher in *Mrp4*^{-/-} mice than in wild-type mice [11]. Similarly, they observed that topotecan concentrations in cerebrospinal fluid 3 hours after the perfusion were about 10-fold higher in *Mrp4*^{-/-} mice. Of note, DeVries *et al.* showed that BCRP (breast cancer resistance protein) and P-gp could also contribute to this phenomenon. In another study performed in mice with a similar design, it was also observed that methotrexate, raltitrexed (two folate analogues) and

cyclophosphamide (an alkylating agent) can significantly accumulate in the brain when MRP4 is not functional [13].

Oseltamivir is an anti-influenza virus drug whose active moiety is called Ro 64-0802. Two hours after an injection of 1mM of Ro 64-0802 to mice, Ose *et al.* reported that its amount in the brain was about 5-times higher in *Mrp4*^{-/-} as compared to control mice [14] (0.32 nmol versus 0.060 nmol). However, the authors also considered organic anion transporter 3 (OAT3/SLC22A8), which is present in the abluminal and luminal membranes of brain capillaries and acknowledged that is difficult to clearly assess its role in brain distribution of the drug. This enlightens an important point: whatever the drug, multiple transporters are involved in membrane crossing processes and it is very difficult to discriminate their respective contributions.

Liver

MRP4 is localized at the basolateral membrane of human (Figure 1C), rat, and mouse hepatocytes. It is also present in the human hepatoma HepG2 cells. It transports, among multiple substances, reduced glutathione and bile salts [15]. Only a few comprehensive studies concerning the impact of MRP4 liver expression on drug pharmacokinetics have been performed. Most of the data derived from *in vitro* studies.

Using different vesicular models expressing MRP4 or not, Ferslew *et al.* demonstrated that enalaprilat (the active metabolite of enalapril, an antihypertensive drug) is a substrate of MRP4 using human sandwich-cultured hepatocytes. The authors observed that the hepatic basolateral efflux clearance of enalaprilat was significantly reduced in presence of the MRP4 inhibitor MK-571 [16].

Interestingly, many transporters, including MRP4, are probably up regulated in the case of primary biliary cirrhosis and ingestion of toxic doses of acetaminophen [17]. In these situations, changes in hepatobiliary efflux transporters expression might modify the process of

drug elimination. Indeed, Aleksunes *et al.* observed increased mRNA and protein expressions of multidrug resistance-associated proteins 2–4 (Mrp2–4) in mouse liver after exposure to a hepatotoxic dose of acetaminophen [18,19]. In another study, they showed that mice treated with acetaminophen reached maximal MRP4/3 up regulation in 48h and that mice pre-treated with acetaminophen had less hepatotoxicity than those treated with placebo [20]. Consequently, the authors concluded that an increased expression of efflux transporters may help to prevent the accumulation of potentially toxic compounds within hepatocytes, thus contributing to acquired resistance [21].

Methotrexate (MTX) is the most widely recommended drug for the treatment of rheumatoid arthritis and is frequently associated to leflunomide in order to increase its clinical efficacy. MTX is a substrate of MRP4. Le Wang *et al.* [22] reported that, in mice, leflunomide significantly decreases the bile excretion of both MTX and its metabolite (7-hydroxy-MTX) and that it increases their concentrations in the liver, kidneys and plasma. Additionally, they observed an up regulation of MRP4 and MRP3 and a down regulation of MRP2 gene expression in the liver. These results suggest an enhanced basolateral efflux of MTX when associated to leflunomide.

Peripheral blood mononuclear cells (PBMC)

Only few data are available to explore the links between the pharmacokinetics of drugs and MRP4-related transport in PBMC.

Neutropenia is a common side effect when treating children for serious infections with long courses of antibiotics. In a study of approximately 100 children, Hahn *et al.* [23] observed that homozygous patients for *MRP4* c.3348 A>G given a prolonged therapy with β -lactam (penicillin, cephalosporin or carbapenem) were 5.3 times (95%CI : 0.6–49.2) more likely to

develop neutropenia ($p = 0.171$); though the pharmacokinetics of the antibiotics remains unchanged in these patients.

Ganciclovir (GCV) is the most widely used treatment for cytomegalovirus infections. However, neutropenia is a frequent associated adverse effect leading to a decrease in the GCV dose or discontinuation of the therapy, thereby favoring viral resistance. In renal transplant patients, Billat *et al.* [24] observed a significant association between GCV-triphosphate intracellular concentrations and the decrease in the neutrophil count over the first 3 months of GCV treatment. The authors identified one MRP4 genetic variant contributing to the decrease of neutrophils count [25] (see section 3.2: genetic polymorphisms).

2.3 The role of MRP4 in drug pharmacodynamics

MRP4 is not considered to be a drug target but it can modify drug pharmacokinetics (as mentioned above), which can contribute to side effects or changes in drug efficacy (i.e. a decrease in MRP4 activity can enhance toxicity by decreasing drug elimination from cells; (figure 3). In addition, MRP4 is directly involved in physiological functions such as platelet aggregation and it participates in the mechanism of drug action. As shown in figure 3, MRP4 has an impact on the response to treatment.

2.3.1 The role of MRP4 in platelets

In platelets, MRP4 is mainly located at the dense granule membrane and to a lesser extent at the plasma membrane (Figure 1D) [26]. At the dense granule membrane, it promotes the storage of ADP which is required for platelet activation and aggregation whereas at the plasma membrane, it promotes efflux from the platelet.

It was reported that patients suffering from Hermansky-Pudlak syndrome (i.e. the δ -storage pool deficiency; a defect in dense granule components) have no MRP4 at the dense granule membrane [26,27]. These patients present extensive bleeding. Mattiello *et al.* reported that

aspirin and salicylic acid can be transported by MRP4 both at the dense granule and at the plasma membrane [28]. After inhibition of MRP4 by dipyridamole (a phosphodiesterase 5 inhibitor) and MK-571, they observed an increase in aspirin and salicylic acid concentrations in the cytoplasm of platelets and a higher COX-1 activity. Additionally, it seems that aspirin modifies the expression of MRP4. In fact, Mattiello *et al.* observed an increased expression of MRP4 at the plasma membrane in patients treated by aspirin after coronary artery bypass graft surgery [28]. Massimi *et al.* [29] confirmed these results as they also observed that platelets MRP4 mRNA was more abundant in patients with chronic aspirin treatment than in patients treated for less than 1 month. Additionally, patients with higher MRP4 mRNA levels had higher serum Thromboxane B2 levels and collagen-induced platelet aggregation (i.e., parameters signing higher platelet aggregation). This suggests that MRP4 has a role in reducing aspirin inhibition of COX-1 when it is overexpressed in platelets.

Temperilli *et al.* observed a similar phenomenon with other NSAIDs [30]. They found a higher expression of MRP4 (mRNA and protein levels) and an increase in ADP-induced platelet aggregation in osteoarthritis patients given NSAIDs for more than 4 weeks. They also demonstrated that DAMI cells (human megakaryocytic cell line) treated with celecoxib, diclofenac, and naproxen had increased expression of MRP4 mRNA. These results suggest that NSAIDs treatment can result in MRP4 overexpression in platelets.

A recent work by Mendes-Silverio *et al.* [31] suggests that MRP4 plays an additional role in platelets. BAY 60-2770 is a soluble guanylyl cyclase activator that potently inhibits human platelet aggregation and adhesion through overstimulation of the cGMP-PKG signaling pathway [32]. In the presence of the MRP4 inhibitor MK 571, the anti-aggregating effect of BAY 60-2770 in collagen- and thrombin-activated platelets was significantly increased. Pre-incubation with MK 571 increased the intracellular and decreased the extracellular levels of cGMP (cyclic GMP) in response to BAY 60-2770, while the cyclic AMP (cAMP) levels

remained unchanged. This resulted in an increase of the phosphorylation of vasodilator-stimulated phosphoprotein at serine 239 in BAY 60-2770-treated platelets. In labelled platelets, BAY 60-2770 reduced the intracellular Ca^{2+} levels, an effect significantly potentiated by MK 571. Flow cytometry assays showed that BAY 60-2770 reduced integrin $\alpha IIb\beta 3$ (GPIIb/IIIa) activation, which was further reduced by MK 571 treatment. Blocking MRP4-mediated efflux of cGMP may be a potential mechanism to enhance the antiplatelet efficacy of soluble guanylyl cyclases activators.

In the light of these in vitro findings, further studies have been performed in MRP4 deficient mice models. Decouture *et al.* [33] showed that arterial occlusion was delayed and tail bleeding time was prolonged in mice lacking MRP4 as compared to control mice.

2.3.2 MRP4 and cancer

The expression of MRP4 in cancer cells is also pivotal for treatment issues as the protein can efflux many anticancer drugs or interfere with physiopathological processes.

Ho *et al.* [34] showed that MRP4 mRNA and protein levels were increased in prostate cancer cells. However, this overexpression was lower in patients pre-operatively treated with androgen castrative therapy, compared to uncastrated prostate cancer patients who had normal testosterone levels. This suggests an androgenic regulation of the transporter. The authors concluded that these data strongly suggested that MRP4 is an androgen-regulated gene important in the progression to prostate cancer and may be a potential drug target. These findings were confirmed using docetaxel resistant C4-2 (C4-2/D) cells (castration resistant prostate cancer cell line) that present an overexpression of MRP4. In fact, treatment with dihydrotestosterone increased MRP4 expression in C4-2/D cells whereas antiandrogenic treatments reversed the sensitivity of these cells to docetaxel chemotherapy by decreasing MRP4 overexpression [35].

Another study performed in CEM cells (human T-lymphoblastic leukemia cell line) demonstrated the role of MRP4 overexpression in 6-mercaptopurine (6-MP) resistance. In this case, MRP4 was up-regulated in tumorous cells but influx transporters were also down-regulated, which resulted in an increase of the efflux of 6-MP and a better survival rate of resistant cells [36]. In clinical settings, the overexpression of both MRP4 and MRP1 were significantly associated with poor prognosis in neuroblastoma [37,38]. These examples clearly show that overexpression of MRP4 in cancer cells contribute to treatment resistances.

MRP4 also manages the efflux of cAMP in human myeloid leukemia cells (U937, HL-60 and KG-1a) and inhibition of MRP4 is associated with an increase in intracellular cAMP, leading to the end of proliferation and promotion of cell differentiation [39]. MRP4 was also found to be highly expressed in non-small cell lung cancer. The inhibition of MRP4 expression with shRNA inhibited cell growth and increased the percentage of cells in G1 phase [40].

2.3.3 MRP4 in infectious diseases

Turizziani *et al.* isolated PMBC from HIV patients and healthy donors and measured MRP4 mRNA expression in lymphocytes T CD4 cells [41]. They observed that MRP4 mRNA expression was significantly higher in HIV patients. Moreover, they showed that treatments can modify MRPs and P-gp mRNA expression.

Clemente *et al.* [42] studied lymphocytes infected with HIV type-1_{NL4.3}, CEM and CEM3TC (overexpressing MRP4) cells treated with zidovudine, emtricitabine and tenofovir (MRP4 substrates) with or without different NSAIDs (ibuprofen, indomethacin and probenecid; MRP4 inhibitors). They observed a reduced efflux of zidovudine (AZT) in presence of these previously quoted inhibitors. Interestingly, the antiretroviral activity (measured by the decrease of p24 antigenemy (Agp24) during 3 days following infection) in infected lymphocytes and CEM3TC cells was significantly enhanced by NSAIDs mediated inhibition

of MRP4. They also demonstrated that activation of peripheral blood lymphocytes from healthy donors with Phytohaemagglutinin can increase MRP4 expression from 6-8% to 25-60%. Additionally, after incubation with AZT, it was observed that MRP4 levels were increased by approximately 10% in total lymphocytes. The authors suggested that MRP4 inhibition can improve anti-retroviral treatment and proposed a possible mechanism of resistance of HIV by MRP4 overexpression. Adachi and al. [43] demonstrated a similar phenomenon with GCV treatment, by demonstrating that cells overexpressing MRP4 are more resistant to GCV cytotoxic effects.

3. Variability of MRP4 activity and consequences in clinical pharmacology

3.1 Drug-drug interactions.

Drug-drug interactions concerning efflux transporters can lead to increased intracellular substrate concentrations through transport inhibition. The increase of transporter expression at the cell membrane can lead to drug exclusion from the cells and to the increase in drug blood concentrations with several consequences depending on the drug properties (increased activity or toxicity or increased elimination of the drugs by the kidney). This section lists examples related to drug-drug interaction with MRP4.

Antiviral therapies:

As discussed above, it was demonstrated in HIV-1 infected T cells that the inhibition of MRP4 by NSAIDs such as ibuprofen and indomethacin led to a significant increase of activity of nucleoside reverse transcriptase inhibitors (zidovudine, abacavir, lamivudine and tenofovir) [42].

Diclofenac is a MRP4 inhibitor [44] and tenofovir is a substrate of MRP4 [9]. A case study has reported a HIV patient treated for a long period of time with tenofovir who developed a severe, biopsy-proven, acute tubular necrosis with proximal tubule dysfunction, after introduction of diclofenac [45]. In a retrospective study conducted in HIV patients, 14.6% of the patients developed acute kidney injury shortly after initiating diclofenac treatment [46], suggesting that the drug-drug interaction between diclofenac and tenofovir is clinically relevant.

Other antiretroviral drugs might be involved in drug-drug interaction with tenofovir. In a study conducted in HIV patients of African origin, an increase in tenofovir trough concentrations was found in patients given lopinavir/ritonavir when compared to other therapies (i.e. tenofovir/emtricitabine/nevirapine; tenofovir/emtricitabine/zidovudine or tenofovir/emtricitabine/efavirenz). Nevertheless, the mean GFR (calculated using the CKD-EPI formula) was not substantially altered after 48 weeks of treatment compared to baseline (-8.2 mL/min/1.73 m², P<0.05) [47]. The authors did not conclude whether the increase in tenofovir concentration was due to an inhibition of influx (by Organic anion transporter OAT1) or efflux (by MRP4 or MRP2). Knowing that lopinavir and ritonavir are mild OAT1/3 and MRP4/2 inhibitors [48,49] and that tenofovir is mainly eliminated by OAT1 and MRP4 [50], it was reported that tenofovir renal clearance can be decreased by 17,5 % in HIV patients treated by lopinavir/ritonavir [51].

Anticancer therapies:

MTX is a substrate of both MRP4 and MRP2 and its transport (and that of its glucuronide conjugates) was found to be inhibited by NSAIDs [44,52] in vesicular transport assays.

When concomitantly administered with MTX, NSAIDs (including indomethacin, ibuprofen, and naproxen) increase its exposure and toxicity. For example, Dupuis *et al.* reported that the

use of MTX with NSAIDs in one patient increased mean MTX half-life [53]. Tracy *et al.* [54] also reported that the apparent systemic clearance of MTX was significantly reduced in patients treated with magnesium trisalicylate, ibuprofen and naproxen. Thyss *et al.* [55] analysed retrospectively 118 cycles of high dose MTX and demonstrated that simultaneous administration of ketoprofen is associated with prolonged detectable MTX levels.

Irinotecan is a drug known to cause severe diarrhea and is another substrate of MRP4. It has been shown that inhibition of cAMP-MRP4 mediated efflux by irinotecan increases cAMP intracellular level near the plasma membrane. This enables the formation of MRP4-CFTR (Cystic fibrosis transmembrane conductance regulator) macromolecular complex (linked by PDZ motif) that activates the CFTR channel and causes diarrhea [56].

An *in vitro* study illustrated the role of MRP4 in resistance to oxazophorine drugs. HepG2 (human liver cancer cell line) and HepG2-MRP4 cells were treated with cyclophosphamide (CP) and ifosfamide (IF) for 48h, with or without inhibitors. The inhibition of CP and IF's MRP4 dependent transport by either DL-buthionine-(S,R)-sulfoximine, celecoxib, diclofenac or MK571 caused an increase in cytotoxicity in HepG2-MRP4 cells compared to untransfected cells [57]. According to these results, there is a probable drug-drug interaction between oxazophorine and some NSAIDs associated with MRP4 inhibition.

3.2 Genetic polymorphisms.

According to dbSNP (<https://www.ncbi.nlm.nih.gov/projects/SNP/>), 30 185 SNPs were reported for *MRP4*, two thirds of which are located in intronic sequences. Some of them have direct or indirect clinical implications (see figure 4, table 2 and 3). In this section, only *MRP4* variations unambiguously associated with clinical outcomes have been discussed.

MRP4 transports many antivirals and anticancer drugs. In all the studies listed in table 1, variants were associated with drug toxicities, efficacy or pharmacokinetics. The direct effects

of MRP4 variants can be difficult to ascertain, since drugs can be transported by other transporters bearing polymorphisms, contributing to the differences observed in clinical outcomes. Some studies also suffer from lack of power. For example, MTX is transported by MRP4 and MRP2 with different affinities [58]. The reduced function of one transporter due to a genetic variation (or to the inhibition through drug-drug interaction) can be compensated by overexpression of the second transporter. In the case of PMEAs (9-(2-phosphonylmethoxyethyl)adenine), initially described as a MRP4 substrate, an up regulation of BCRP in various tissues was described in MRP4 Knock Out mice and was associated with decreased tissue concentrations of PMEAs [59]. Based on this observation, it has been confirmed that BCRP transports and confers resistance to the purine prodrug Bis(POM)PMEA also known as adefovir dipivoxil used in treatment for Hepatitis B. MRP4 expression in kidneys was also found to be increased in MRP2 deficient rats strain as compared to wild type rats but the efflux of cAMP (a MRP4 substrate) was not increased [60]. Both of these transporters are expressed at the apical membranes of proximal tubule cells and this study suggested that MRP4 can take over MRP2 substrates but it has not been tested with common substrates of these transporters. Indeed, the urinary excretion of cysteinyl leukotrienes and acetaminophen–glucuronide conjugate known as MRP2 substrates were increased in MRP2 deficient rat and Dubin-Johnson patients [61-63], suggesting a compensatory MRP4 transporter up regulation.

4. Conclusion

This review provides a better understanding regarding MRP4 drug transport and its implication in efficacy or toxicity. Based on recommendations from the International Transporter Consortium [64], regulatory instances such as the European Medicines Agency

(EMA) and the Food and Drugs Administration (FDA) currently recommend investigating the role of only 7 transporters in the process of drug development (i.e. OAT1, OAT3, OCT2, OATP1B1, OATP1B1, P-gp and BCRP). MRP4 is not yet included in the list. Special attention should be given to MRP4 when dealing with anti-cancer, anti-infectious drugs or NSAIDs.

References

- [1] K. Lee, M.G. Belinsky, D.W. Bell, J.R. Testa, G.D. Kruh, Isolation of MOAT-B, a widely expressed multidrug resistance-associated protein/canalicular multispecific organic anion transporter-related transporter, *Cancer Res.* 58 (1998) 2741–2747.
- [2] R.A.M.H. van Aabel, P.H.E. Smeets, J.G.P. Peters, R.J.M. Bindels, F.G.M. Russel, The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP, *J. Am. Soc. Nephrol.* 13 (2002) 595–603.
- [3] Membrane transporters in drug development, *Nature Publishing Group.* 9 (2010) 215–236. doi:10.1038/nrd3028.
- [4] B. Chantemargue, F. Di Meo, K. Berka, N. Picard, H. Arnion, M. Essig, et al., Structural patterns of the human ABCC4/MRP4 exporter in lipid bilayers rationalize clinically observed polymorphisms, *Pharmacological Research.* 133 (2018) 318–327. doi:10.1016/j.phrs.2018.02.029.
- [5] A. Ivanyuk, F. Livio, J. Biollaz, T. Buclin, Renal Drug Transporters and Drug Interactions, *Clinical Pharmacokinetics.* (2017) 1–68. doi:10.1007/s40262-017-0506-8.
- [6] F. Russel, J. Koenderink, R. Masereeuw, Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules, *Trends in Pharmacological Sciences.* 29 (2008) 200–207. doi:10.1016/j.tips.2008.01.006.
- [7] L. Ci, H. Kusuhara, M. Adachi, J.D. Schuetz, K. Takeuchi, Y. Sugiyama, Involvement of MRP4 (ABCC4) in the luminal efflux of ceftizoxime and cefazolin in the kidney, *Molecular Pharmacology.* 71 (2007) 1591–1597. doi:10.1124/mol.106.031823.
- [8] M. Hasegawa, H. Kusuhara, M. Adachi, J.D. Schuetz, K. Takeuchi, Y. Sugiyama, Multidrug Resistance-Associated Protein 4 Is Involved in the Urinary Excretion of Hydrochlorothiazide and Furosemide, *J. Am. Soc. Nephrol.* 18 (2006) 37–45. doi:10.1681/ASN.2005090966.
- [9] T. Imaoka, H. Kusuhara, M. Adachi, J.D. Schuetz, K. Takeuchi, Y. Sugiyama, Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir, *Molecular Pharmacology.* 71 (2007) 619–627. doi:10.1124/mol.106.028233.
- [10] A.T. Nies, G. Jedlitschky, J. König, C. Herold-Mende, H.H. Steiner, H.P. Schmitt, et al., Expression and immunolocalization of the multidrug resistance proteins, MRP1–MRP6 (ABCC1–ABCC6), in human brain, *Neuroscience.* 129 (2004) 349–360. doi:10.1016/j.neuroscience.2004.07.051.
- [11] M. Leggas, M. Adachi, G.L. Scheffer, D. Sun, P. Wielinga, G. Du, et al., MRP4

- confers resistance to topotecan and protects the brain from chemotherapy, *Mol. Cell. Biol.* 24 (2004) 7612–7621. doi:10.1128/MCB.24.17.7612-7621.2004.
- [12] N.A. de Vries, J. Zhao, E. Kroon, T. Buckle, J.H. Beijnen, O. van Tellingen, P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan, *Clin. Cancer Res.* 13 (2007) 6440–6449. doi:10.1158/1078-0432.CCR-07-1335.
- [13] K. Kanamitsu, H. Kusuhara, J.D. Schuetz, K. Takeuchi, Y. Sugiyama, Investigation of the Importance of Multidrug Resistance-Associated Protein 4 (Mrp4/Abcc4) in the Active Efflux of Anionic Drugs Across the Blood-Brain Barrier, *Journal of Pharmaceutical Sciences.* 106 (2017) 2566–2575. doi:10.1016/j.xphs.2017.04.040.
- [14] A. Ose, M. Ito, H. Kusuhara, K. Yamatsugu, M. Kanai, M. Shibasaki, et al., Limited Brain Distribution of [3R,4R,5S]-4-Acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate Phosphate (Ro 64-0802), a Pharmacologically Active Form of Oseltamivir, by Active Efflux across the Blood-Brain Barrier Mediated by Organic Anion Transporter 3 (Oat3/Slc22a8) and Multidrug Resistance-Associated Protein 4 (Mrp4/Abcc4), *Drug Metabolism and Disposition.* 37 (2009) 315–321. doi:10.1124/dmd.108.024018.
- [15] M. Rius, Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane, *Hepatology.* 38 (2003) 374–384. doi:10.1053/jhep.2003.50331.
- [16] B.C. Ferslew, K. Köck, A.S. Bridges, K.L.R. Brouwer, Role of multidrug resistance-associated protein 4 in the basolateral efflux of hepatically derived enalaprilat, *Drug Metab. Dispos.* 42 (2014) 1567–1574. doi:10.1124/dmd.114.057554.
- [17] S.N. Barnes, L.M. Aleksunes, L. Augustine, G.L. Scheffer, M.J. Goedken, A.B. Jakowski, et al., Induction of hepatobiliary efflux transporters in acetaminophen-induced acute liver failure cases, *Drug Metabolism and Disposition.* 35 (2007) 1963–1969. doi:10.1124/dmd.107.016170.
- [18] L.M. Aleksunes, A.M. Slitt, N.J. Cherrington, M.S. Thibodeau, C.D. Klaassen, J.E. Manautou, Differential expression of mouse hepatic transporter genes in response to acetaminophen and carbon tetrachloride, *Toxicological Sciences.* 83 (2005) 44–52. doi:10.1093/toxsci/kfi013.
- [19] L.M. Aleksunes, G.L. Scheffer, A.B. Jakowski, I.M. Pruijboom-Brees, J.E. Manautou, Coordinated expression of multidrug resistance-associated proteins (Mrps) in mouse liver during toxicant-induced injury, *Toxicological Sciences.* 89 (2006) 370–379. doi:10.1093/toxsci/kfi332.
- [20] L.M. Aleksunes, S.N. Campion, M.J. Goedken, J.E. Manautou, Acquired Resistance to Acetaminophen Hepatotoxicity is Associated with Induction of Multidrug Resistance-Associated Protein 4 (Mrp4) in Proliferating Hepatocytes, *Toxicological Sciences.* 104 (2008) 261–273. doi:10.1093/toxsci/kfn093.
- [21] M. Banerjee, M.W. Carew, B.A. Roggenbeck, B.D. Whitlock, H. Naranmandura, X.C. Le, et al., A novel pathway for arsenic elimination: human multidrug resistance protein 4 (MRP4/ABCC4) mediates cellular export of dimethylarsinic acid (DMAV) and the diglutathione conjugate of monomethylarsonous acid (MMAIII), *Molecular Pharmacology.* 86 (2014) 168–179. doi:10.1124/mol.113.091314.
- [22] L. Wang, L. Ma, Y. Lin, X. Liu, L. Xiao, Y. Zhang, et al., Leflunomide Increases Hepatic Exposure to Methotrexate and Its Metabolite by Differentially Regulating Multidrug Resistance-Associated Protein Mrp2/3/4 Transporters via Peroxisome Proliferator-Activated Receptor α Activation, *Molecular Pharmacology.* 93 (2018) 563–574. doi:10.1124/mol.117.110593.
- [23] A. Hahn, T. Fukuda, D. Hahn, T. Mizuno, R.W. Frenck, A.A. Vinks,

- Pharmacokinetics and pharmacogenomics of β -lactam-induced neutropenia, *Pharmacogenomics*. 17 (2016) 547–559. doi:10.2217/pgs-2015-0008.
- [24] P.-A. Billat, J.-B. Woillard, M. Essig, F.-L. Sauvage, N. Picard, S. Alain, et al., Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity? *J. Antimicrob. Chemother.* 71 (2016) 484–489. doi:10.1093/jac/dkv342.
- [25] P.-A. Billat, T. Ossman, F. Saint-Marcoux, M. Essig, J.-P. Rerolle, N. Kamar, et al., Multidrug Resistance-Associated Protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients, *Pharmacological Research*. (2017) 1–29. doi:10.1016/j.phrs.2016.07.012.
- [26] G. Jedlitschky, The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage, *Blood*. 104 (2004) 3603–3610. doi:10.1182/blood-2003-12-4330.
- [27] G. Jedlitschky, M. Cattaneo, L.E. Lubenow, D. Rosskopf, A. Lecchi, A. Artoni, et al., Role of MRP4 (ABCC4) in platelet adenine nucleotide-storage: evidence from patients with delta-storage pool deficiencies, *Am. J. Pathol.* 176 (2010) 1097–1103. doi:10.2353/ajpath.2010.090425.
- [28] T. Mattiello, R. Guerriero, L.V. Lotti, E. Trifirò, M.P. Felli, A. Barbarulo, et al., Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting, *J. Am. Coll. Cardiol.* 58 (2011) 752–761. doi:10.1016/j.jacc.2011.03.049.
- [29] I. Massimi, L.V. Lotti, F. Temperilli, M. Mancone, G. Sardella, S. Calcagno, et al., Enhanced platelet MRP4 expression and correlation with platelet function in patients under chronic aspirin treatment, *Thromb. Haemost.* 116 (2016) 1100–1110. doi:10.1160/TH16-04-0316.
- [30] F. Temperilli, M. Di Franco, I. Massimi, M.L. Guarino, M.P. Guzzo, G. Valesini, et al., Nonsteroidal anti-inflammatory drugs in-vitro and in-vivo treatment and Multidrug Resistance Protein 4 expression in human platelets, *Vascul. Pharmacol.* 76 (2016) 11–17. doi:10.1016/j.vph.2015.06.016.
- [31] C.B. Mendes-Silverio, C.H. Lescano, T. Zaminelli, C. Sollon, G.F. Anhô, E. Antunes, et al., Activation of soluble guanylyl cyclase with inhibition of multidrug resistance protein inhibitor-4 (MRP4) as a new antiplatelet therapy, *Biochemical Pharmacology*. 152 (2018) 165–173. doi:10.1016/j.bcp.2018.03.028.
- [32] C.B. Mendes-Silverio, L.O.S. Leiria, R.P. Morganti, G.F. Anhô, S. Marcondes, F.Z. Mónica, et al., Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway, *PLoS ONE*. 7 (2012) e47223. doi:10.1371/journal.pone.0047223.
- [33] B. Decouture, E. Dreano, T. Belleville-Rolland, O. Kuci, B. Dizier, A. Bazaa, et al., Impaired platelet activation and cAMP homeostasis in MRP4-deficient mice, *Blood*. 126 (2015) 1823–1830. doi:10.1182/blood-2015-02-631044.
- [34] L.L. Ho, J.G. Kench, D.J. Handelsman, G.L. Scheffer, P.D. Stricker, J.G. Grygiel, et al., Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer, *The Prostate*. 68 (2008) 1421–1429. doi:10.1002/pros.20809.
- [35] Y.-F. Li, H.-H. Ji, Z.-L. Zhang, T.-T. Zhang, W. Gan, S.-F. Zhang, Targeting MRP4 expression by anti-androgen treatment reverses MRP4-mediated docetaxel resistance in castration-resistant prostate cancer, *Oncol Lett.* 14 (2017) 1748–1756. doi:10.3892/ol.2017.6357.
- [36] X.-X. Peng, Z. Shi, V.L. Damaraju, X.-C. Huang, G.D. Kruh, H.-C. Wu, et al., Up-

- regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine, *Leukemia Research*. 32 (2008) 799–809. doi:10.1016/j.leukres.2007.09.015.
- [37] M.D. Norris, J. Smith, K. Tanabe, P. Tobin, C. Flemming, G.L. Scheffer, et al., Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro, *Mol. Cancer Ther.* 4 (2005) 547–553. doi:10.1158/1535-7163.MCT-04-0161.
- [38] M.D. Norris, S.B. Bordow, G.M. Marshall, P.S. Haber, S.L. Cohn, M. Haber, Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma, *N. Engl. J. Med.* 334 (1996) 231–238. doi:10.1056/NEJM199601253340405.
- [39] S. Copsel, C. Garcia, F. Diez, M. Vermeulem, A. Baldi, L.G. Bianciotti, et al., Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation, *J. Biol. Chem.* 286 (2011) 6979–6988. doi:10.1074/jbc.M110.166868.
- [40] X. Zhao, Y. Guo, W. Yue, L. Zhang, M. Gu, Y. Wang, ABCC4 is required for cell proliferation and tumorigenesis in non-small cell lung cancer, *Onco Targets Ther.* 7 (2014) 343–351. doi:10.2147/OTT.S56029.
- [41] O. Turriziani, N. Gianotti, F. Falasca, A. Boni, A.R. Vestri, A. Zoccoli, et al., Expression levels of MDR1, MRP1, MRP4, and MRP5 in peripheral blood mononuclear cells from HIV infected patients failing antiretroviral therapy, *J. Med. Virol.* 80 (2008) 766–771. doi:10.1002/jmv.21152.
- [42] M.I. Clemente, S. Álvarez, M.J. Serramía, O. Turriziani, M. Genebat, M. Leal, et al., Non-steroidal anti-inflammatory drugs increase the antiretroviral activity of nucleoside reverse transcriptase inhibitors in HIV type-1-infected T-lymphocytes: role of multidrug resistance protein 4, *Antivir. Ther. (Lond.)*. 14 (2008) 1101–1111. doi:10.3851/IMP1468.
- [43] M. Adachi, J. Sampath, L.-B. Lan, D. Sun, P. Hargrove, R. Flatley, et al., Expression of MRP4 confers resistance to ganciclovir and compromises bystander cell killing, *J. Biol. Chem.* 277 (2002) 38998–39004. doi:10.1074/jbc.M203262200.
- [44] A.A.K. El-Sheikh, J.J.M.W. van den Heuvel, J.B. Koenderink, F.G.M. Russel, Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport, *Journal of Pharmacology and Experimental Therapeutics*. 320 (2007) 229–235. doi:10.1124/jpet.106.110379.
- [45] J. Morelle, L. Labriola, M. Lambert, J.-P. Cosyns, F. Jouret, M. Jadoul, Tenofovir-related acute kidney injury and proximal tubule dysfunction precipitated by diclofenac: a case of drug-drug interaction, *Clin. Nephrol.* 71 (2009) 567–570.
- [46] M. Bickel, P. Khaykin, C. Stephan, K. Schmidt, M. Buettner, K. Amann, et al., Acute kidney injury caused by tenofovir disoproxil fumarate and diclofenac co-administration, *HIV Medicine*. 14 (2013) 633–638. doi:10.1111/hiv.12072.
- [47] M.P. Lê, R. Landman, S. Koulla-Shiro, C. Charpentier, P.-S. Sow, M.-B. Diallo, et al., Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients: ANRS 12115 DAYANA substudy, *J. Antimicrob. Chemother.* 70 (2015) 1517–1521. doi:10.1093/jac/dku532.
- [48] T. Cihlar, A.S. Ray, G. Laflamme, J.E. Vela, L. Tong, M.D. Fuller, et al., Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors, *Antivir. Ther. (Lond.)*. 12 (2007) 267–272.
- [49] W.F.W. Bierman, G.L. Scheffer, A. Schoonderwoerd, G. Jansen, M.A. van Agtmael,

- S.A. Danner, et al., Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines, *J. Antimicrob. Chemother.* 65 (2010) 1672–1680. doi:10.1093/jac/dkq209.
- [50] J.J. Kohler, S.H. Hosseini, E. Green, A. Abuin, T. Ludaway, R. Russ, et al., Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters, *Lab. Invest.* 91 (2011) 852–858. doi:10.1038/labinvest.2011.48.
- [51] J.J. Kiser, M.L. Carten, C.L. Aquilante, P.L. Anderson, P. Wolfe, T.M. King, et al., The Effect of Lopinavir/Ritonavir on the Renal Clearance of Tenofovir in HIV-infected Patients, *Clinical Pharmacology & Therapeutics.* 83 (2007) 265–272. doi:10.1038/sj.clpt.6100269.
- [52] A. Kawase, T. Yamamoto, S. Egashira, M. Iwaki, Stereoselective Inhibition of Methotrexate Excretion by Glucuronides of Nonsteroidal Anti-inflammatory Drugs via Multidrug Resistance Proteins 2 and 4, *J. Pharmacol. Exp. Ther.* 356 (2016) 366–374. doi:10.1124/jpet.115.229104.
- [53] L.L. Dupuis, G. Koren, A. Shore, E.D. Silverman, R.M. Laxer, Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis, *J. Rheumatol.* 17 (1990) 1469–1473.
- [54] T.S. Tracy, K. Krohn, D.R. Jones, J.D. Bradley, S.D. Hall, D.C. Brater, The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis, *Eur. J. Clin. Pharmacol.* 42 (1992) 121–125.
- [55] A. Thyss, G. Milano, J. Kubar, M. Namer, M. Schneider, Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen, *Lancet.* 1 (1986) 256–258.
- [56] C. Moon, W. Zhang, A. Ren, K. Arora, C. Sinha, S. Yarlagadda, et al., Compartmentalized accumulation of cAMP near complexes of multidrug resistance protein 4 (MRP4) and cystic fibrosis transmembrane conductance regulator (CFTR) contributes to drug-induced diarrhea, *J. Biol. Chem.* 290 (2015) 11246–11257. doi:10.1074/jbc.M114.605410.
- [57] J. Zhang, K.-Y. Ng, P.C. Ho, Interaction of oxazaphosphorines with multidrug resistance-associated protein 4 (MRP4), *Aaps J.* 12 (2010) 300–308. doi:10.1208/s12248-010-9189-x.
- [58] A.A.K. El-Sheikh, R. Greupink, H.M. Wortelboer, J.J.M.W. van den Heuvel, M. Schreurs, J.B. Koenderink, et al., Interaction of immunosuppressive drugs with human organic anion transporter (OAT) 1 and OAT3, and multidrug resistance-associated protein (MRP) 2 and MRP4, *Translational Research.* (2016) 1–11. doi:10.1016/j.trsl.2013.08.003.
- [59] K. Takenaka, J.A. Morgan, G.L. Scheffer, M. Adachi, C.F. Stewart, D. Sun, et al., Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution, *Cancer Res.* 67 (2007) 6965–6972. doi:10.1158/0008-5472.CAN-06-4720.
- [60] C. Chen, A.L. Slitt, M.Z. Dieter, Y. Tanaka, G.L. Scheffer, C.D. Klaassen, Up-regulation of Mrp4 expression in kidney of Mrp2-deficient TR- rats, *Biochemical Pharmacology.* 70 (2005) 1088–1095. doi:10.1016/j.bcp.2005.06.019.
- [61] M. Huber, A. Guhlmann, P.L. Jansen, D. Keppler, Hereditary defect of hepatobiliary cysteinyl leukotriene elimination in mutant rats with defective hepatic anion excretion, *Hepatology.* 7 (1987) 224–228.
- [62] E. Mayatepek, W.D. Lehmann, Defective hepatobiliary leukotriene elimination in patients with the Dubin-Johnson syndrome, *Clin. Chim. Acta.* 249 (1996) 37–46.
- [63] C. Chen, G.E. Hennig, J.E. Manautou, Hepatobiliary excretion of acetaminophen

- glutathione conjugate and its derivatives in transport-deficient (TR-) hyperbilirubinemic rats, *Drug Metab. Dispos.* 31 (2003) 798–804.
- [64] K.M. Hillgren, D. Keppler, A.A. Zur, K.M. Giacomini, B. Stieger, C.E. Cass, et al., Emerging Transporters of Clinical Importance: An Update From the International Transporter Consortium, *Clinical Pharmacology & Therapeutics.* 94 (2013) 52–63. doi:10.1038/clpt.2013.74.
- [65] S. Likanonsakul, B. Suntisuklappon, R. Nitiyanontakij, W. Prasithsirikul, E.E. Nakayama, T. Shioda, et al., A Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 Infection, *PLoS ONE.* 11 (2016) e0147724. doi:10.1371/journal.pone.0147724.
- [66] J.J. Kiser, C.L. Aquilante, P.L. Anderson, T.M. King, M.L. Carten, C.V. Fletcher, Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients, *J. Acquir. Immune Defic. Syndr.* 47 (2008) 298–303.
- [67] K. Rungtivasuwan, A. Avihingsanon, N. Thammajaruk, S. Mitruk, D.M. Burger, K. Ruxrungham, et al., Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients, *Antimicrob. Agents Chemother.* 59 (2015) 3240–3245. doi:10.1128/AAC.04930-14.
- [68] P.L. Anderson, J. Lamba, C.L. Aquilante, E. Schuetz, C.V. Fletcher, Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study, *J. Acquir. Immune Defic. Syndr.* 42 (2006) 441–449. doi:10.1097/01.qai.0000225013.53568.69.
- [69] L.-C. Gao, D. Wang, F.-Q. Liu, Z.-Y. Huang, H.-G. Huang, G.-H. Wang, et al., Influence of PTGS1, PTGFR, and MRP4 genetic variants on intraocular pressure response to latanoprost in Chinese primary open-angle glaucoma patients, *Eur. J. Clin. Pharmacol.* 71 (2015) 43–50. doi:10.1007/s00228-014-1769-8.
- [70] M. Banerjee, V. Marensi, G. Conseil, X.C. Le, Susan P.C. Cole, E.M. Leslie, Polymorphic variants of MRP4/ABCC4 differentially modulate the transport of methylated arsenic metabolites and physiological organic anions, *Biochemical Pharmacology.* 120 (2016) 72–82. doi:10.1016/j.bcp.2016.09.016.
- [71] P. Nicoletti, V.M. Cartsos, P.K. Palaska, Y. Shen, A. Floratos, A.I. Zavras, Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3, *Oncologist.* 17 (2012) 279–287. doi:10.1634/theoncologist.2011-0202.
- [72] J.-Y. Han, Y.-S. Lee, E.S. Shin, J.-A. Hwang, S. Nam, S.-H. Hong, et al., A genome-wide association study of survival in small-cell lung cancer patients treated with irinotecan plus cisplatin chemotherapy, *Pharmacogenomics J.* 14 (2014) 20–27. doi:10.1038/tpj.2013.7.
- [73] S. de Denus, J.L. Rouleau, D.L. Mann, G.S. Huggins, T.P. Cappola, S.H. Shah, et al., A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials, *Pharmacogenomics J.* 17 (2017) 192–200. doi:10.1038/tpj.2016.4.
- [74] H. Ban, A. Andoh, H. Imaeda, A. Kobori, S. Bamba, T. Tsujikawa, et al., The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease, *J. Gastroenterol.* 45 (2010) 1014–1021. doi:10.1007/s00535-010-0248-y.
- [75] M.A.H. den Hoed, E. Lopez-Lopez, M.L. te Winkel, W. Tissing, J.D.E. de Rooij, A. Gutierrez-Camino, et al., Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia, *Pharmacogenomics J.*

- 15 (2015) 248–254. doi:10.1038/tpj.2014.63.
- [76] E. Lopez-Lopez, J. Ballesteros, M.A. Piñan, J. Sanchez de Toledo, N. Garcia de Andoin, P. Garcia-Miguel, et al., Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia, *Pharmacogenet. Genomics*. 23 (2013) 53–61. doi:10.1097/FPC.0b013e32835c3b24.
- [77] S. Angelini, M.A. Pantaleo, G. Ravegnini, C. Zenesini, G. Cavrini, M. Nannini, et al., Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy, *Pharmacological Research*. 68 (2013) 1–6. doi:10.1016/j.phrs.2012.10.015.
- [78] S.-K. Low, K. Kiyotani, T. Mushiroda, Y. Daigo, Y. Nakamura, H. Zembutsu, Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients, *J. Hum. Genet.* 54 (2009) 564–571. doi:10.1038/jhg.2009.79.
- [79] M. Whirl-Carrillo, E.M. McDonagh, J.M. Hebert, L. Gong, K. Sangkuhl, C.F. Thorn, et al., Pharmacogenomics Knowledge for Personalized Medicine, *Clinical Pharmacology & Therapeutics*. 92 (2012) 414–417. doi:10.1038/clpt.2012.96.

Figure legends

- **Figure 1:** MRP4 tissue localization. Arrows indicate the substrate transport direction. (A) MRP4 is localized at the basolateral membrane of the choroid plexus epithelium and also at the luminal side of brain capillaries. (B) In the kidney, MRP4 is localized at the apical side of proximal tubules. (C) In the liver, it is expressed at the basolateral side of hepatocytes. (D) In platelets, it can be found at the dense granule as well as at the plasma membrane.
- **Figure 2:** MRP4 structure. Recent determination taken from and reprinted with permission from Chantemargue et al. [4]. TMH = Transmembrane helix, L1 and L0 = Linker 1 and 0, NBD= nucleotide binding domain, ICD= intra-cytoplasmic domain
- **Figure 3:** Impact of MRP4 overexpression on drug efflux. Cells expressing MRP4 (blue) A. In normal cell life conditions; B. in case of overexpression (long term treatment for cancer, infection...), substrate (blue dots) efflux is increased. This may result in resistance to treatment.

- **Figure 4:** Overview of relevant SNPs. In grey, MRP4 gene localization on chromosome 13. Black boxes represent exons, full lines correspond to introns and dash lines to untranslated regions. Red stars show the different SNPs listed in this review.

Table 1: MRP4 substrates and inhibitors reported in the literature and their related clinical application fields, adapted from Russel and Ivanyuk [5,6]

| Drugs | Substrates (Yes/No/ND) (Km if available) | Inhibitor (Yes/No/ND) (IC50 if available) | Clinical application field: drug class |
|-----------------------------------|---|--|---|
| Simvastatin | ND | Yes* | Cardiovascular system: hypolipidemic agents |
| Dipyridamole | ND | Yes (<1-12 μ M) | Cardiovascular system: antithrombotic agents |
| Ticlopidine | ND | Yes | |
| Furosemide | Yes | Yes | Cardiovascular system: <i>Diuretics</i> |
| Hydrochlorothiazide | Yes | Yes* | |
| Irbesartan | ND | Yes (10 μ M) | Cardiovascular system: <i>Renin-angiotensin system</i> |
| Losartan | ND | Yes* | |
| Olmesartan | Yes (26 μ M) | Yes | |
| DHEAS | Yes (2 μ M) | Yes | Endocrinology: <i>Sex corticosteroids</i> |
| Estradiol-17 β -glucuronide | Yes (30 μ M) | Yes | |
| Tamoxifen | ND | Yes* | |
| Cefazoline | Yes* (80 μ M) | Yes | Anti-infectious agents: <i>β-lactam antibiotics</i> |
| Cefmetazole | Yes* (28 μ M) | Yes | |
| Cefotaxime | Yes | Yes | |
| Ceftizoxime | Yes* (18 μ M) | Yes | |
| Piperacillin | Yes* | ND | |

Table 1 (Cont'd)

| Drugs | Substrates (Yes/No/ND) (Km if available) | Inhibitor (Yes/No/ND) (IC50 if available) | Clinical application field: drug class |
|-------------------------------|---|--|--|
| Nitrofurantoin | ND | Yes* | Anti-infectious agents: <i>Other antibacterials</i> |
| Sulfasalazine | ND | Yes* | |
| Micafungin | ND | Yes* | |
| Adefovir | Yes* (> 1000 μ M) | ND | Anti-infectious agents: <i>Antiviral agents</i> |
| Tenofovir disoproxil fumarate | Yes* (> 1000 μ M) | ND | |
| Leucovorin | Yes (640 μ M) | Yes | |
| Methotrexate | Yes* (220-1300 μ M) | Yes | Antineoplastic agents |
| Mitoxantrone | ND | No (enhanced [³ H]-MTX efflux) | |
| Sorafenib | ND | Yes* | |
| Topotecan | Yes | ND | |
| Mycophenolic acid | Yes | Yes* | |
| Celecoxib | 35 (μ M) | Yes | Non-steroidal anti-inflammatory drugs |
| Flurbiprofen | ND | Yes* | |
| Ibuprofen | ND | Yes* | |
| Indomethacin | 5-22 (μ M) | Yes* | |
| Naproxen | ND | Yes* | |
| Sulindac | Yes (2 μ M) | Yes* | |

Table 1 (Cont'd)

| Drugs | Substrates (Yes/No/ND) (Km if available) | Inhibitor (Yes/No/ND) (IC50 if available) | Clinical application field: drug class |
|---------------------------|---|--|--|
| Allopurinol | ND | No (Enhanced urate efflux) | Anti-gout and uricosuric drugs |
| Benzbromarone | | Yes* | |
| Probenecid | Yes (100 μ M) | Yes | |
| Edaravone and glucuronide | Yes (9.8 μ M) | ND | Central nervous system drugs: <i>Others</i> |
| Sildenafil | Yes (20 μ M) | Yes | Other xenobiotics |

Table footnotes: * indicates substantial contribution of MRP4 to drug transport or important inhibition potency (i.e. for substrates: drug eliminated by tubular secretion for at least 25% of its total clearance, predominantly through MRP4; for inhibitors, Ki or IC50 within the 10-fold range of plasma unbound maximal concentration, or when a pharmacokinetic interaction clinically significant was reported). ND indicates no data. Km : Michaelis Menten's constant ; IC 50: half maximal inhibitory concentration.

Table 2: list of the 12 *ABCC4* variants associated with substantial clinical consequences
(according to <https://www.pharmgkb.org>)

| Variant ID | Nucleotide change (consequences) | Drug impacted | Consequences | Level of proof | Ref |
|------------|-----------------------------------|-------------------------------------|---|----------------|------------------|
| rs1059751 | c.*879T>C (3'-UTR SNP) | Tenofovir | Increase of beta2-microglobulinuria in tenofovir HIV patients related to kidney tubular dysfunction | 3 | [65] |
| rs1751034 | c.3348G>C/A (Missense Variant) | Tenofovir | <i>ABCC4</i> c.3348G allele carriers had higher TFV-DP concentrations than wild type carriers. | 2B | [66] |
| rs3742106 | c.*38T>G (3'-UTR SNP) | Tenofovir | Patients carrying <i>ABCC4</i> c.*38 TG or GG genotype had, on average, a 30% higher mean tenofovir plasma concentration than patients carrying the TT genotype | 3 | [67] |
| | | Zidovudine | <i>ABCC4</i> c.*38G allele carriers had 20% higher 3TC-triphosphate concentrations than non-carriers | | [68] |
| rs11568658 | c.559G>T (Missense Variant) | Latanoprost (Val)ganciclovir | <i>ABCC4</i> c.559T carrier had significantly lower decrease in intraocular pressure than non-carriers at day 7 and day 30 of latanoprost treatment. <i>ABCC4</i> c.559T carriers had significant higher risk of neutropenia following valganciclovir treatment than non-carriers. | 3 | [69] [25] |

| | | | | | |
|-------------------|--------------------------------|--|---|---|------|
| | | Methylated arsenic metabolites (MMA(GS) ₂) | Decrease of MRP4 mediated efflux in vesicular transport assay | | [70] |
| rs1678387 | g.240795A>G (Intronic variant) | Biphosphonates | Allele A is weakly associated with an increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to allele G. | 3 | [71] |
| rs16950650 | g.183269G>A (Intron variant) | Cisplatin Irinotecan | Variant allele carriers had shorter overall survival for small-cell lung cancer when treated by irinotecan and cisplatin than wild type carriers. | 3 | [72] |
| rs17268282 | g.33387C>A (Intron variant) | Furosemide | This variant was associated with weight loss when using furosemide in decompensated heart failure patients. | 3 | [73] |
| rs3765534 | c.2269G>A (Missense Variant) | Azathioprine, Mercaptopurine | Increase of 6-Thioguanine nucleotide levels and decrease of white blood cells in carriers of the variant. | 3 | [74] |
| rs7317112 | g.35178T>C (Intron variant) | Methotrexate (MTX) | Wild type genotype was associated with more frequent mucositis in Acute lymphoblastic leukemia patients treated with MTX | 3 | [75] |
| rs9516519 | c.*1372A>G/C (3'-UTR SNP) | Methotrexate (MTX) | TT genotype was associated with higher MTX plasma levels compared to GG + GT genotype when exposed to MTX in children with acute | 3 | [76] |

Leukemia, B-Cell.

| | | | | | |
|------------------|---------------------------------|------------------|--|---|------|
| rs9561765 | g.275458C>T (Intron variant) | Imatinib | <i>ABCC4</i> TT genotype was associated with reduced time to progression disease in gastrointestinal stromal tumors | 3 | [77] |
| rs9561778 | g.244986C>T (Intron variant) | Cyclophosphamide | This variant was associated with gastrointestinal toxicity and leukopenia/neutropenia when using Cyclophosphamide based combination in breast cancer patient | 3 | [78] |

Table footnotes: Nucleotide changes are given according to *ABCC4* transcript variant 1 (i.e. NM_005845.4) or to the RefSeq for intronic variants. PharmGKB criteria for levels of evidence [79] are the following: **2B**: Annotation for a variant–drug combination with moderate evidence of an association. The association must be replicated, but there may be some studies that do not show statistical significance, and/or the effect size may be small. **3**: Annotation for a variant–drug combination based on a single significant (not yet replicated) study or annotation for a variant–drug combination evaluated in multiple studies but lacking clear evidence of an association.


Table 3: Minor allelic frequencies (MAF) of MRP4 variants in different ethnic groups

| MAF | AFR | AMR | EAS | EUR | SAS |
|---------|---|--|--|---|---|
| < 1 % | rs3765534; rs11568658 | | rs9516519; rs17268282; rs11568695 | rs3765534; rs16950650; rs11568695 | rs11568695 |
| 1-10 % | rs9561765; rs17268282; rs1678387 | rs9561765; rs3765534; rs17268282; rs16950650; rs1678387; rs11568695; rs11568658 | rs3765534; rs16950650 | rs9561765; rs17268282; rs1678387; rs11568658 | rs9561765; rs9516519; rs3765534; rs17268282; rs16950650; rs1678387; rs11568658 |
| 10-20 % | rs9561778; rs16950650; rs11568695 | rs9561778; rs9516519 | rs11568658 | rs9561778; rs9516519; rs1751034 | rs9561778; rs1751034 |
| > 20 % | rs9516519; rs3742106; rs1751034; rs1059751; rs7317112 | rs7317112; rs3742106; rs1751034; rs1059751 | rs9561778; rs9561765; rs7317112; rs3742106; rs1751034; rs1678387; rs1059751 | rs7317112; rs3742106; rs1059751 | rs7317112; rs3742106; rs1059751 |


AFR: Africans, AMR: Americans, EAS: East Asian, EUR: European, SAS: South Asian

A: Brain 

Brain capillaries





Choroid plexus




B: Kidney 

Proximal tubule



C: Liver 

Hepatocytes



D: Platelet




Figure 1

Graphical abstract

